ARQT Stock Price, Arcutis Biotherapeutics Quote, Chart

Market Summary

USD9.20+0.08

Market Closed

0.88%

ARQT Alerts

1 major insider sales recently.

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)
Losses in recent quarter

ARQT Stock Price

View Fullscreen

ARQT RSI Chart

ARQT Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-4.89

Price/Sales (Trailing)

9.99

Price/Free Cashflow

-5.35

ARQT Price/Sales (Trailing)

ARQT Profitability

Operating Margin

96.97%

Return on Equity

-96.66%

Return on Assets

-45.43%

Free Cashflow Yield

-18.69%

ARQT Fundamentals

ARQT Revenue

Revenue (TTM)

106.4M

Rev. Growth (Yr)

1.7K%

Rev. Growth (Qtr)

266.47%

ARQT Earnings

Earnings (TTM)

-217.4M

Earnings Growth (Yr)

55.83%

Earnings Growth (Qtr)

46.62%

Breaking Down ARQT Revenue

Last 7 days

17.1%

Last 30 days

-10.4%

Last 90 days

-1.3%

Trailing 12 Months

-2.9%

How does ARQT drawdown profile look like?

ARQT Financial Health

Current Ratio

9.89

Debt/Equity

0.9

Debt/Cashflow

-0.98

ARQT Investor Care

Shares Dilution (1Y)

88.47%

Diluted EPS (TTM)

-2.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	106.4M	0	0	0
2023	17.7M	31.6M	45.6M	59.6M
2022	0	0	0	3.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Arcutis Biotherapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	matsuda masaru	sold	-43,828	8.7378	-5,016	see remark
May 02, 2024	burnett patrick	sold	-83,489	8.7378	-9,555	see remarks
May 02, 2024	watanabe todd franklin	sold	-120,433	8.7378	-13,783	see remarks
May 02, 2024	moore matthew richard	sold	-40,901	8.7378	-4,681	svp and chief business officer
May 01, 2024	moore matthew richard	acquired	-	-	4,166	svp and chief business officer
Apr 10, 2024	topper david joseph	acquired	-	-	110,000	chief financial officer
Mar 04, 2024	heron patrick j	bought	199,994	9.5	21,052	-
Mar 04, 2024	burnett patrick	sold	-53,181	11.1212	-4,782	see remarks
Mar 04, 2024	moore matthew richard	sold	-38,568	11.1212	-3,468	svp and chief business officer
Mar 04, 2024	matsuda masaru	sold	-41,815	11.1212	-3,760	see remark

Which funds bought or sold ARQT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	VIMA LLC	sold off	-100	-9,690	-	-%
May 17, 2024	Ikarian Capital, LLC	new	-	5,843,350	5,843,350	0.64%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.88	36,799	78,844	-%
May 16, 2024	COMERICA BANK	added	276	3,069	3,360	-%
May 16, 2024	JANE STREET GROUP, LLC	added	32.96	1,597,400	2,116,140	-%
May 16, 2024	Colony Group, LLC	new	-	558,000	558,000	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	3.65	325,000	474,000	-%
May 15, 2024	Ghisallo Capital Management LLC	sold off	-100	-323,000	-	-%
May 15, 2024	Frazier Life Sciences Management, L.P.	added	0.24	58,753,700	87,062,200	3.67%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	834	8,134,750	8,428,740	-%

Are Funds Buying or Selling ARQT?

Are funds buying ARQT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARQT

No. of Funds

Unveiling Arcutis Biotherapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	jennison associates llc	10.8%	12,128,533	SC 13G/A
Mar 06, 2024	frazier life sciences viii, l.p.	7.8%	8,785,284	SC 13D/A
Feb 14, 2024	prudential financial inc	10.47%	0	SC 13G/A
Feb 13, 2024	polar capital holdings plc	6.67%	6,297,688	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	9.99%	9,534,837	SC 13G/A
Feb 13, 2024	vanguard group inc	5.19%	4,896,513	SC 13G
Feb 12, 2024	morgan stanley	6.5%	6,093,497	SC 13G
Feb 12, 2024	rubric capital management lp	7.04%	6,644,530	SC 13G
Feb 08, 2024	jennison associates llc	9.6%	9,066,082	SC 13G
Jan 31, 2024	point72 asset management, l.p.	5.1%	4,836,116	SC 13G

Recent SEC filings of Arcutis Biotherapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	144	Notice of Insider Sale Intent
May 17, 2024	144	Notice of Insider Sale Intent
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 02, 2024	144	Notice of Insider Sale Intent
May 02, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Arcutis Biotherapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Arcutis Biotherapeutics Inc News

Latest updates

Arcutis Biotherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)							(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Revenue	266.5%	50.00	14.00	38.00	5.00	3.00	2.00	1.00
Cost Of Revenue	-	-	-	1.00	1.00	1.00	0.00	0.00
Costs and Expenses	-	81.00	-	-	-	79.00	-	-
Operating Expenses	-	-	-	75.00	72.00	79.00	71.00	105
S&GA Expenses	12.6%	55.00	49.00	48.00	46.00	43.00	37.00	35.00
R&D Expenses	-2.7%	23.00	24.00	26.00	25.00	35.00	54.00	30.00
Interest Expenses	-3.6%	7.00	8.00	8.00	7.00	7.00	7.00	5.00
Income Taxes	2392.3%	0.00	0.00	3.00	-	-	-	-
Net Income	46.6%	-35.38	-66.28	-44.76	-70.99	-80.10	-72.02	-107
Net Income Margin	53.5%	-2.04*	-4.40*	-5.87*	-10.45*	-18.52*	-84.50*	-
Free Cashflow	43.8%	-31.60	-56.25	-44.05	-66.76	-80.43	-71.19	-67.70

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	40.2%	479	341	293	321	379	449	509	300	364	408	387	433	471	298	198	232	254	107
Current Assets	41.7%	468	330	282	309	368	437	497	295	359	403	382	428	466	293	194	228	254	106
Cash Equivalents	113.5%	191	89.00	107	105	81.00	55.00	83.00	63.00	71.00	98.00	53.00	91.00	290	67.00	46.00	172	191	63.00
Inventory	0.9%	13.00	13.00	14.00	10.00	9.00	8.00	4.00	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-11.0%	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	0.00	0.00	0.00	0.00
Liabilities	0.4%	254	253	246	240	240	240	238	105	110	110	24.00	18.00	20.00	28.00	25.00	23.00	13.00	6.00
Current Liabilities	1.4%	47.00	47.00	42.00	37.00	37.00	38.00	37.00	27.00	33.00	33.00	19.00	13.00	15.00	23.00	21.00	19.00	12.00	5.00
Long Term Debt	0.5%	203	202	201	200	199	198	197	73.00	73.00	72.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	202	201	200	199	198	197	73.00	73.00	72.00	-	-	-	-	-	-	-	-
Shareholder's Equity	153.7%	225	89.00	47.00	81.00	140	210	271	195	254	298	363	414	451	271	173	209	242	-
Retained Earnings	-3.6%	-1,017	-981	-915	-870	-799	-719	-647	-540	-472	-408	-336	-280	-238	-202	-167	-129	-94.28	-66.30
Additional Paid-In Capital	16.0%	1,242	1,071	963	952	940	930	920	737	727	706	700	695	689	473	341	339	336	1.00
Shares Outstanding	19.3%	116	97.00	62.00	62.00	61.00	61.00	53.00	51.00	51.00	49.00	50.00	50.00	-	-	-	-	-	-
Float	-	-	-	-	487	-	-	-	878	-	-	-	1,082	-	-	-	620	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	43.8%	-31,603	-56,244	-43,984	-66,485	-80,344	-71,065	-67,695	-61,980	-56,975	-51,709	-40,884	-35,831	-46,203	-32,571	-33,691	-25,761	-21,010	-16,797	-10,722	-8,243	-7,074
Share Based Compensation	14.5%	10,030	8,757	9,999	10,578	9,479	9,264	8,789	8,096	6,533	5,686	5,363	4,340	8,503	2,643	2,261	2,049	990	455	154	139	76.00
Cashflow From Investing	53.9%	-28,697	-62,186	45,549	89,118	107,751	42,201	-197,262	52,565	15,297	23,499	3,471	-164,919	61,996	-75,892	-91,711	6,105	-20,326	-35,999	21,096	-2,152	-9,270
Cashflow From Financing	62.9%	161,764	99,289	867	1,067	100	962	284,989	1,131	14,716	72,881	63.00	1,188	207,815	129,380	-437	309	168,893	92,955	-20.00	168	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ARQT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 21,569	$ 2,781
Other revenue	28,000	0
Total revenues	49,569	2,781
Operating expenses:
Cost of sales	3,256	783
Research and development	23,141	35,345
Selling, general, and administrative	54,794	42,918
Total operating expenses	81,191	79,046
Loss from operations	(31,622)	(76,265)
Other income (expense):
Other income, net	4,044	3,207
Interest expense	(7,480)	(7,042)
Loss before income taxes	(35,058)	(80,100)
Provision for income taxes	324	0
Net loss	(35,382)	(80,100)
Other comprehensive income (loss):
Unrealized income (loss) on marketable securities	(116)	724
Foreign currency translation adjustment	(21)	(52)
Total other comprehensive income (loss)	(137)	672
Comprehensive loss	$ (35,519)	$ (79,428)
Per share information:
Net loss per share, basic (in USD per share)	$ (0.32)	$ (1.31)
Net loss per share, diluted (in USD per share)	$ (0.32)	$ (1.31)
Weighted-average shares used in computing net loss per share, basic (in shares)	111,048,525	61,169,089
Weighted-average shares used in computing net loss per share, diluted (in shares)	111,048,525	61,169,089

ARQT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 190,097	$ 88,398
Restricted cash	617	925
Marketable securities	213,769	183,463
Trade receivables, net	37,154	25,807
Inventories	13,247	13,134
Prepaid expenses and other current assets	13,178	18,704
Total current assets	468,062	330,431
Property, plant, and equipment, net	1,369	1,539
Intangible assets, net	6,250	6,438
Operating lease right-of-use asset	2,264	2,361
Other assets	596	596
Total assets	478,541	341,365
Current liabilities:
Accounts payable	12,969	11,992
Accrued liabilities	33,584	33,941
Operating lease liability	756	735
Total current liabilities	47,309	46,668
Operating lease liability, noncurrent	3,181	3,382
Long-term debt, net	202,803	201,799
Other long-term liabilities	306	849
Total liabilities	253,599	252,698
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 115,505,437 and 96,787,343 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	12	9
Additional paid-in capital	1,242,349	1,070,558
Accumulated other comprehensive loss	(133)	4
Accumulated deficit	(1,017,286)	(981,904)
Total stockholders’ equity	224,942	88,667
Total liabilities and stockholders’ equity	$ 478,541	$ 341,365

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

CEO	Mr. Todd Franklin Watanabe M.A.
WEBSITE	arcutis.com
INDUSTRY	Biotechnology
EMPLOYEES	268

Arcutis Biotherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Arcutis Biotherapeutics Inc? What does ARQT stand for in stocks?

ARQT is the stock ticker symbol of Arcutis Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcutis Biotherapeutics Inc (ARQT)?

As of Fri May 17 2024, market cap of Arcutis Biotherapeutics Inc is 1.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARQT stock?

You can check ARQT's fair value in chart for subscribers.

What is the fair value of ARQT stock?

You can check ARQT's fair value in chart for subscribers. The fair value of Arcutis Biotherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcutis Biotherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARQT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcutis Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ARQT is over valued or under valued. Whether Arcutis Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Arcutis Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARQT.

What is Arcutis Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ARQT's PE ratio (Price to Earnings) is -4.89 and Price to Sales (PS) ratio is 9.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARQT PE ratio will change depending on the future growth rate expectations of investors.